Aureka Biotechnologies
AI-powered digital biology for protein therapeutics and antibody discovery
Aureka Biotechnologies develops AI-powered digital-biology systems for discovering protein therapeutics and antibody treatments. The Laguna Hills company combines high-throughput functional screening with AI-based therapeutic design. Its $100M Series B announced on August 11, 2026 was led by Granite Asia, with HighLight Capital and Matrix Partners China among the disclosed participants.
Biotechnology
📍 Laguna Hills, CA
Founded 2023
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Aureka Biotechnologies going public?
No. Aureka Biotechnologies is private and has not filed to go public. There is no S-1 on file.
What is Aureka Biotechnologies' valuation in 2026?
No confirmed valuation is on record for Aureka Biotechnologies. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Aureka Biotechnologies filed an S-1?
No public S-1 is on file for Aureka Biotechnologies.
Who are Aureka Biotechnologies' investors?
Aureka Biotechnologies' investors include Granite Asia, HighLight Capital, Matrix Partners China.
Is Aureka Biotechnologies publicly traded — can you buy Aureka Biotechnologies stock?
No. Aureka Biotechnologies is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Aureka Biotechnologies on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Growth
$100M Series B to expand AI-native therapeutic discovery
Last Round
Series B — $100M (Aug 2026) · Lead: Granite Asia
Fundraising Status
Series B · $100M · 2 mo ago
private1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series B | $100M | Aug 2026 | Granite Asia | — |
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Aureka Biotechnologies — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-30. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for Aureka Biotechnologies as of 2026-09-23. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Investors
Granite Asia · HighLight Capital · Matrix Partners China
Products
- AI-powered digital-biology platform for protein therapeutics
- High-throughput antibody discovery and design platform
BiotechnologyAIDrug DiscoveryProtein TherapeuticsSeries B
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.